Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Neuren Pharmaceuticals Ltd

NEU.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Pharmaceuticals ·

Australia Mid Cap Analyst: BUY

Last Close

$16.60

▼ -0.51%

Market Cap $2.10B · Vol 362.66K

Key Metrics

P/E Ratio

100.75

FWD: 48.61

Market Cap

$2.10B

Mid Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

+49.71%

YoY

RSI (14)

93.21

Momentum

Beta

2.08

vs Market

52W High

$16.82

1.05% below

52W Low

$7.79

115.40% above

Volume

362.66K

Avg 536.54K

P/B

6.96

Price-to-book

ROE

8.67%

Return on equity

Free Float

86.66%

Public shares

Shariah Compliance8 STANDARDS

✗ Neuren Pharmaceuticals Ltd (NEU.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NEU.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.21%

+40.50%

+82.49%

+83.92%

YTD

+26.01%

+41.78%

+103.06%

+956.31%

Financials & Valuation

TTM · Annual

Total Revenue	$51.25M
Net Income	$20.31M
Revenue Growth (YoY)	-78.24%
Gross Margin	100.00%
Operating Margin	44.52%
Net Profit Margin	39.63%
ROE	8.67%
ROA · ROIC	10.35% · 8.67%

P/E Ratio	100.75
Forward P/E (FY1)	48.61
PEG Ratio	-1.02
P/S	31.68
P/B	6.96
P/FCF	19.41
EPS Growth	+49.71%
Outstanding Shares	126.77M

Technical Indicators

50-Day SMA	$11.88
200-Day SMA	$11.14
RSI (14)	93.21
Beta	2.08
52-Week High	$16.82
52-Week Low	$7.79

Volume Today	362.66K
Avg Daily Volume (30D)	536.54K
Relative Volume	0.68x
Volatility (10D)	72.13
Volatility (30D)	53.44
Free Float	86.66%

Analyst Consensus

BUY

Current Price $16.60

Mean Target $17.81

52W Low$7.79 52W High$16.82

Current

Target

$7.79 $16.82

Current Analyst target

+7.26% upside potential · 5 analysts

Identifiers

ExchangeASX

FIGIBBG001SFQMB4

ISINNZNEUE0001S8

CountryAustralia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateAug 25, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product, NNZ-2591, is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.